Listeria monocytogenes-based bivalent Lm-LLO immunotherapy for the treatment of HER2/neu positive and triple negative breast cancer and its impact on immunosuppression

被引：0
|
作者：
Wallecha, A. [1 ]
Ramos, K. [1 ]
Malinina, I. [1 ]
Singh, R. [1 ]
机构：
[1] Advaxis Inc, Princeton, NJ USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P4-04-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-04-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human
    V Shahabi
    M M Seavey
    P C Maciag
    S Rivera
    A Wallecha
    Cancer Gene Therapy, 2011, 18 : 53 - 62
  • [2] Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human
    Shahabi, V.
    Seavey, M. M.
    Maciag, P. C.
    Rivera, S.
    Wallecha, A.
    CANCER GENE THERAPY, 2011, 18 (01) : 53 - 62
  • [3] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    Medical Oncology, 2009, 26 : 335 - 343
  • [4] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [5] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [6] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Jie Li
    Maoguang Ma
    Xuesong Yang
    Maolei Zhang
    Jingyan Luo
    Huangkai Zhou
    Nunu Huang
    Feizhe Xiao
    Bingquan Lai
    Weiming Lv
    Nu Zhang
    Molecular Cancer, 19
  • [7] DIFFERENCES IN METASTATIC POTENTIAL IN HER2 POSITIVE AND TRIPLE NEGATIVE INFLAMMATORY BREAST CANCER
    Kolarevic, Daniela
    Tomasevic, Zorica
    BREAST, 2011, 20 : S38 - S39
  • [8] Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
    Li, Jie
    Ma, Maoguang
    Yang, Xuesong
    Zhang, Maolei
    Luo, Jingyan
    Zhou, Huangkai
    Huang, Nunu
    Xiao, Feizhe
    Lai, Bingquan
    Lv, Weiming
    Zhang, Nu
    MOLECULAR CANCER, 2020, 19 (01)
  • [9] MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer
    Radojicic, Jelena
    Zaravinos, Apostolos
    Vrekoussis, Thomas
    Kafousi, Maria
    Spandidos, Demetrios A.
    Stathopoulos, Efstathios N.
    CELL CYCLE, 2011, 10 (03) : 507 - 517
  • [10] Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer.
    Ghamande, Sharad A.
    Platt, Daniel
    Wheatley, Donna
    Rungruang, Bunja Jane
    Janik, John Edward
    Khleif, Samir
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345